Provided by Tiger Trade Technology Pte. Ltd.

Quantum Biopharma Ltd.

3.44
+0.320010.26%
Post-market: 3.450.0100+0.29%18:24 EDT
Volume:1.19M
Turnover:4.26M
Market Cap:20.05M
PE:-0.43
High:3.94
Open:3.20
Low:3.15
Close:3.12
52wk High:38.25
52wk Low:2.07
Shares:5.83M
Float Shares:5.25M
Volume Ratio:5.56
T/O Rate:22.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.9660
EPS(LYR):-12.4923
ROE:-346.87%
ROA:-67.64%
PB:2.90
PE(LYR):-0.28

Loading ...

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

GlobeNewswire
·
Apr 02

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

GlobeNewswire
·
Apr 01

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:50 AM

Reuters
·
Mar 30

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

GlobeNewswire
·
Mar 30

Quantum Biopharma Provides Corporate Update

GlobeNewswire
·
Mar 28

Press Release: Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

Dow Jones
·
Mar 27

Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate

Benzinga
·
Mar 27

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

GlobeNewswire
·
Mar 26

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

GlobeNewswire
·
Mar 23

Press Release: Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Dow Jones
·
Mar 21

Quantum BioPharma Provides Corporate Update

GlobeNewswire
·
Mar 12

Quantum BioPharma Provides Corporate Update

GlobeNewswire
·
Mar 11

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

GlobeNewswire
·
Dec 23, 2025

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

GlobeNewswire
·
Dec 20, 2025

Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC

GlobeNewswire
·
Dec 01, 2025

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC

GlobeNewswire
·
Nov 28, 2025

Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

GlobeNewswire
·
Nov 26, 2025

Quantum Biopharma Ltd expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Nov 08, 2025

Quantum BioPharma's digital asset portfolio has achieved a $572,000 return since the beginning of the year

Blockbeats
·
Nov 07, 2025

Press Release: Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Dow Jones
·
Nov 07, 2025